Penn Received $7.8 Million from ARPA-H to Advance Lymphatic Imaging and AI-Driven Disease Detection
The project is led by Maxim Itkin, MD, Professor of Radiology at Penn Medicine and the director of Penn’s Center for Lymphatic Disorders.
T Cells Targeting Misformed Proteins to Treat Neurodegenerative and Muscular Diseases
By targeting disease-specific proteins, this antigen-specific immunotherapy aims to selectively eliminate damaged cells, potentially offering a more precise and effective treatment approach.
Penn Expands its Immunology Research
Penn’s newly developed seven-story facility at 3600 Civic Center Boulevard will bring together labs across disciplines to advance breakthroughs in immune health, autoimmunity, and infectious diseases.
Dispatch Bio Developing Tumor-Agnostic Immunotherapy Targeting Solid Tumors
The technology, now in preclinical development, has the potential to overcome the limitations of traditional cancer treatments for solid tumors.
Opus Genetics Reports Positive Pediatric Data from its Clinical Trial Evaluating Investigational Gene Therapy for a Rare Eye Disorder
These findings suggest OPGx-LCA5, Opus Genetics' investigational gene augmentation therapy, could improve vision for patients previously considered untreatable.
GEMMA Biotherapeutic Announces Clinical Trial Authorization for New Gene Therapy Treatment
Its novel gene therapy for spinal muscular atrophy type 1 (SMA1) has been cleared for clinical trial in Brazil by ANVISA.
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel
Rese-cel is an experimental CAR T-cell therapy designed to “reset” the immune system in people with autoimmune diseases.
Sonura’s Novel NICU Technology Featured in the Philadelphia Inquirer
Now being tested in a clinical trial at Penn, the device aims to reduce infant stress, support bonding, and potentially improve growth and feeding for preterm babies.
Avisi Technologies Announces First Patient Implanted with Glaucoma Treatment Device in Clinical Trial
Avisi treated its first patient in a clinical trial to evaluate the safety and effectiveness of its novel VisiPlate® glaucoma treatment device.
BlueWhale Bio Raises $5M, Partners with Avantor, Inc.
BlueWhale Bio was co-founded by Carl June, MD, the Richard W. Vague Professor in Immunotherapy and James Riley, PhD, Professor of Microbiology, both at Penn Medicine.